The recent trade deal between the United States and the European Union has significant implications for the medtech industry. President Donald Trump and European Commission President Ursula von der Leyen announced that most imports from the EU would face a 15% tariff under the new pact. This flat rate tariff covers a wide range of EU exports, including cars, semiconductors, and pharmaceutical products.
While von der Leyen assured that pharmaceuticals were included under the 15% tariff, Trump mentioned that potential tariffs on such products would not be part of the deal. The agreement also includes provisions for the EU to purchase $750 billion worth of U.S. energy exports over the next three years and invest $600 billion into the country. Additionally, zero-for-zero tariffs have been established for strategic products such as aircraft parts, chemicals, semiconductor equipment, agricultural products, and critical raw materials. This trade deal sets the stage for a new era of economic cooperation between the US and the EU, with implications for various industries, including the rapidly evolving field of medtech.
Read more on medtechdive.com